VAV2 is a guanine nucleotide exchange factor (GEF) that activates Rac1 and other Rho family GTPases, serving as a central signaling hub in multiple cellular processes 1. VAV2 functions primarily through phosphotyrosine-dependent recruitment to activated receptor tyrosine kinases, including EGFR and Fc-gamma receptors, where it catalyzes GTP loading onto small G-proteins to regulate cell migration, proliferation, and cytoskeletal remodeling 2. Beyond its canonical GEF activity, VAV2 participates in DNA damage repair by facilitating Ku70/Ku80 complex formation during non-homologous end joining 3. Functionally, VAV2 exhibits context-dependent roles: it promotes physiological insulin secretion in pancreatic β-cells but also mediates metabolic stress-induced cellular dysfunction 1. In cancer, VAV2 is frequently overexpressed and drives multiple hallmarks including proliferation, migration, and therapeutic resistance 24. Clinically, VAV2 represents an attractive therapeutic target; its inhibition reverses antibody-induced desmoplasia in breast cancer 5, improves radiotherapy sensitivity in esophageal cancer 3, and enhances immunotherapy efficacy in pancreatic cancer 6. VAV2 overexpression correlates with poor clinical prognosis in prostate cancer 2, and notably, VAV2 can exist on extrachromosomal circular DNA, contributing to therapeutic resistance mechanisms 4.